Stoke Therapeutics, Inc. (STOK) — closed signal from September 28, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 27, 2025.
Predicted vs. what happened
What happened
Reached its target in 16 days.
The thesis — published September 28, 2025
This looks suitable for a 3 month trade because new study results for its Dravet treatment showed steady seizure reductions and gains in thinking skills, suggesting first-in-class potential. Investor mood is very strong. The recent average price is turning up, while some momentum signs are still behind, so buying on dips makes sense. Finances are reasonable for a research-stage biotech, and interest in the sector improved after the Fed cut.
Primary drivers
- Study showed lasting seizure cuts and cognitive gains in Dravet patients
- Very strong investor mood and rising interest across healthcare stocks
- Recent average price improving while some momentum signals lag behind
- Biotech attention improved after the Fed cut, bringing fresh interest
How it played out
STOK: target reached in 16 days
Lyra published STOK at $24.14 on 2025-09-28 for a short-term window ending 2025-12-27. The thesis expected 35% growth to $32.59. It pointed to Dravet study results with lasting seizure cuts and cognitive gains, very strong investor mood, an improving recent average price, lagging momentum signals, reasonable finances for a research-stage biotech, and improved biotech attention after the Fed cut.
Inside the window, STOK reached a peak of $38.69 on 2025-10-16, a 60.3% gain. The target was reached in 16 days. By the end of the window, the stock was $31.92. The published thesis played out.
What happened during the window
On 2025-11-04, Stoke reported third-quarter results, including $10.6 million in revenue and a loss of $0.65 per share, according to Investors.com. On 2025-12-16, Investors.com wrote that Stoke was collaborating with Biogen on zorevunersen for Dravet syndrome.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.